Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Sale and supply of puberty blockers to be banned indefinitely

Medical experts found an ‘unacceptable safety risk’ in the continued prescription of puberty blockers to children
gettyimages

Medical experts found an ‘unacceptable safety risk’ in the continued prescription of puberty blockers to children

The Department of Health and Social Care (DHSC) has decided to enforce an ‘indefinite’ ban on the sale and supply of puberty blockers via private prescriptions for the treatment of gender incongruence and/or gender dysphoria in under-18s in the UK.

This decision follows official advice from the Commission on Human Medicines (CHM), which found an "unacceptable safety risk" in the continued prescription of puberty blockers to children.


The CHM, tasked by the health secretary and Northern Ireland Minister for Health to evaluate the safety of gonadotropin-releasing hormone (GnRH) agonists for puberty suppression, issued eight recommendations.

It advised that a statutory indefinite ban be placed on the use of puberty blockers until its three recommended structures are in place to support safe UK prescribing.

Legislation to make this order indefinite will be updated today and will be reviewed in 2027.

The NHS stopped the routine prescription of puberty blocker treatments to under 18s in March 2024, following the Cass Review into gender identity services.

In May 2024, a temporary ban was introduced after the Cass Review concluded that there was insufficient evidence to prove the safety of these treatments.

Health secretary Wes Streeting justified the decision, stating, “Children’s healthcare must always be evidence-led.

“We need to act with caution and care when it comes to this vulnerable group of young people, and follow the expert advice.”

He also announced plans to work with NHS England to launch new gender identity services, providing holistic health and wellbeing support.

Additionally, a clinical trial into the use of puberty blockers will begin next year to establish a clear evidence base for the use of this medicine.

Professor Steve Cunningham, vice-chair of the Commission, noted that the indefinite ban is made in the context of a significant waiting list for gender specialist services in the UK.

“In making this decision, CHM considered the safety, actual and potential, of using GnRH agonists to suppress puberty, and also risks to children and young people associated with accessing GnRH agonists via alternative routes,” she said.

Dr Hilary Cass, the author of the independent review of gender identity services for children and young people, described puberty blockers as “powerful drugs with unproven benefits and significant risks.”

She recommended that they should “only be prescribed following a multi-disciplinary assessment and within a research protocol.”

Dr Cass supported the government’s decision to continue restrictions outside NHS protocols, where these essential safeguards are not being provided.

James Palmer, NHS medical director for specialised services, welcomed the move, saying it “closes a loophole that posed a risk to the safety of children and young people.”

He acknowledged that the decision may be difficult for affected young people and their families, and assured that targeted mental health support will be available.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) will develop new standards based on the CHM's recommendations.

A clinical trial, as suggested by the Cass Review, will be initiated by the National Institute for Health and Care Research (NIHR) in collaboration with NHS England to determine the effectiveness of puberty suppression and the safety of prolonged treatment, aiming to recruit the first patients by spring 2025.

Restrictions overview

  • Continue restrictions on the dispensing of puberty blockers prescribed by private UK-registered prescribers for gender incongruence and/or gender dysphoria to under-18s not already taking them.
  • Ban on sale and supply of the medicine from prescribers registered in the European Economic Area or Switzerland for any reason to those under 18.
  • NHS patients already on puberty blockers for gender dysphoria or other medical purposes can continue to access them.
  • Local NHS mental health services in England will offer targeted support to those whose access to puberty blockers is discontinued and who are not on the waiting list of children’s gender services.

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less